Literature DB >> 17827451

Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers.

Dan G Duda1, Rakesh K Jain, Christopher G Willett.   

Abstract

Although still in very early stages of clinical development, the combination of antiangiogenics with contemporary chemoradiotherapy regimens has emerged as a feasible and promising approach to many cancers. We review the rationale and the current understanding of antiangiogenics and their therapeutic potential in combination with chemoradiotherapy. Finally, we offer a perspective on future research directions aimed at making this complex therapeutic approach successful in the clinic.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17827451      PMCID: PMC2686120          DOI: 10.1200/JCO.2007.11.3985

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  61 in total

Review 1.  Molecular regulation of vessel maturation.

Authors:  Rakesh K Jain
Journal:  Nat Med       Date:  2003-06       Impact factor: 53.440

2.  PET concerns in bevacizumab treatment.

Authors:  Carsten Goessl; Zarko Grozdanovic
Journal:  Nat Med       Date:  2004-06       Impact factor: 53.440

3.  Pathology: cancer cells compress intratumour vessels.

Authors:  Timothy P Padera; Brian R Stoll; Jessica B Tooredman; Diane Capen; Emmanuelle di Tomaso; Rakesh K Jain
Journal:  Nature       Date:  2004-02-19       Impact factor: 49.962

4.  Glioblastoma cells block radiation-induced programmed cell death of endothelial cells.

Authors:  Charles K Brown; Nikolai N Khodarev; Jianqing Yu; Tricia Moo-Young; Edwardine Labay; Thomas E Darga; Mitchell C Posner; Ralph R Weichselbaum; Helena J Mauceri
Journal:  FEBS Lett       Date:  2004-05-07       Impact factor: 4.124

5.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

6.  Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy.

Authors:  Linda W Chan; Marsha A Moses; Elizabeth Goley; Mary Sproull; Thierry Muanza; C Norman Coleman; William D Figg; Paul S Albert; Cynthia Ménard; Kevin Camphausen
Journal:  J Clin Oncol       Date:  2004-02-01       Impact factor: 44.544

7.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.

Authors:  Christopher G Willett; Yves Boucher; Emmanuelle di Tomaso; Dan G Duda; Lance L Munn; Ricky T Tong; Daniel C Chung; Dushyant V Sahani; Sanjeeva P Kalva; Sergey V Kozin; Mari Mino; Kenneth S Cohen; David T Scadden; Alan C Hartford; Alan J Fischman; Jeffrey W Clark; David P Ryan; Andrew X Zhu; Lawrence S Blaszkowsky; Helen X Chen; Paul C Shellito; Gregory Y Lauwers; Rakesh K Jain
Journal:  Nat Med       Date:  2004-01-25       Impact factor: 53.440

8.  Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.

Authors:  Fairooz Kabbinavar; Herbert I Hurwitz; Louis Fehrenbacher; Neal J Meropol; William F Novotny; Grazyna Lieberman; Susan Griffing; Emily Bergsland
Journal:  J Clin Oncol       Date:  2003-01-01       Impact factor: 44.544

9.  Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11.

Authors:  H Wildiers; G Guetens; G De Boeck; E Verbeken; B Landuyt; W Landuyt; E A de Bruijn; A T van Oosterom
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

10.  Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors.

Authors:  Ricky T Tong; Yves Boucher; Sergey V Kozin; Frank Winkler; Daniel J Hicklin; Rakesh K Jain
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

View more
  37 in total

Review 1.  Antiangiogenic therapy for glioblastoma: current status and future prospects.

Authors:  Tracy T Batchelor; David A Reardon; John F de Groot; Wolfgang Wick; Michael Weller
Journal:  Clin Cancer Res       Date:  2014-11-15       Impact factor: 12.531

2.  Flow cytometric identification and functional characterization of immature and mature circulating endothelial cells.

Authors:  Julie A Mund; Myka L Estes; Mervin C Yoder; David A Ingram; Jamie Case
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-01-26       Impact factor: 8.311

3.  Synergistic effect of antiangiogenic nanotherapy combined with methotrexate in the treatment of experimental inflammatory arthritis.

Authors:  Hui-Fang Zhou; Grace Hu; Samuel A Wickline; Gregory M Lanza; Christine T N Pham
Journal:  Nanomedicine (Lond)       Date:  2010-09       Impact factor: 5.307

4.  Chemoradiotherapy for esophageal cancer.

Authors:  Geoffrey Neuner; Ashish Patel; Mohan Suntharalingam
Journal:  Gastrointest Cancer Res       Date:  2009-03

Review 5.  Bevacizumab in the treatment of metastatic breast cancer: friend or foe?

Authors:  Alberto J Montero; Mauricio Escobar; Gilberto Lopes; Stefan Glück; Charles Vogel
Journal:  Curr Oncol Rep       Date:  2012-02       Impact factor: 5.075

6.  Induced interleukin-33 expression enhances the tumorigenic activity of rat glioma cells.

Authors:  Kuan-Min Fang; Chung-Shi Yang; Tzu-Chien Lin; Ti-Chun Chan; Shun-Fen Tzeng
Journal:  Neuro Oncol       Date:  2013-12-09       Impact factor: 12.300

7.  Nanomedicines for Endothelial Disorders.

Authors:  Bomy Lee Chung; Michael J Toth; Nazila Kamaly; Yoshitaka J Sei; Jacob Becraft; Willem J M Mulder; Zahi A Fayad; Omid C Farokhzad; YongTae Kim; Robert Langer
Journal:  Nano Today       Date:  2015-12-01       Impact factor: 20.722

8.  Piperine, a dietary phytochemical, inhibits angiogenesis.

Authors:  Carolyn D Doucette; Ashley L Hilchie; Robert Liwski; David W Hoskin
Journal:  J Nutr Biochem       Date:  2012-08-16       Impact factor: 6.048

9.  Molecular and clinical aspects of targeting the VEGF pathway in tumors.

Authors:  Grzegorz Korpanty; Laura A Sullivan; Elizabeth Smyth; Desmond N Carney; Rolf A Brekken
Journal:  J Oncol       Date:  2010-06-10       Impact factor: 4.375

10.  An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients.

Authors:  François Ducray; Aurélien de Reyniès; Olivier Chinot; Ahmed Idbaih; Dominique Figarella-Branger; Carole Colin; Lucie Karayan-Tapon; Hervé Chneiweiss; Michel Wager; François Vallette; Yannick Marie; David Rickman; Emilie Thomas; Jean-Yves Delattre; Jérôme Honnorat; Marc Sanson; François Berger
Journal:  Mol Cancer       Date:  2010-09-07       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.